A Novel MOA-Based Bioluminescent Bioassay for Quantitative Measurement of Anti-VEGF Antibody Potency and Stability

Part # PS348


Jennifer Wilkinson, Matt Robers, Frank Fan and Mei Cong
Promega Corporation, 2800 Woods Hollow Rd, Madison WI 53711

Vascular endothelial growth factor (VEGF) is an important signaling molecule that stimulates angiogenesis, increases vascular permeability, and enhances tumor invasion and survival. We have developed a bioluminescent reporter-based bioassay that measures VEGF stimulation/inhibition of KDR (VEGFR2). This assay overcomes many of the limitations of the current endothelial cell proliferation assays, and can be used for the discovery and development of novel biologic therapies aimed at either inducing or inhibiting the VEGF response.

The bioassay utilizes cryopreserved thaw-and use cells, eliminating the need for cell culture. This assay format offers the benefits of convenience, reproducibility and transferability. The assay can be performed in less than 7 hours, which is a significant improvement over a 4–5 day traditional cell proliferation assay. Finally, using the anti-VEGF antibody drug bevacizumab, we demonstrate that the assay is suitable for potency and stability studies per ICH guidelines.


Printed in USA.